Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Akebia Therapeutics (AKBA)

Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 399,271
  • Shares Outstanding, K 218,181
  • Annual Sales, $ 194,620 K
  • Annual Income, $ -51,930 K
  • EBIT $ -35 M
  • EBITDA $ 2 M
  • 60-Month Beta 0.70
  • Price/Sales 2.05
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 115.26% ( -0.13%)
  • Historical Volatility 45.28%
  • IV Percentile 64%
  • IV Rank 29.50%
  • IV High 319.44% on 01/12/24
  • IV Low 29.81% on 08/21/24
  • Put/Call Vol Ratio 0.05
  • Today's Volume 123
  • Volume Avg (30-Day) 827
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 26,905
  • Open Int (30-Day) 22,984

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.04
  • Number of Estimates 2
  • High Estimate -0.04
  • Low Estimate -0.04
  • Prior Year 0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7400 +5.17%
on 12/18/24
2.1700 -15.67%
on 12/03/24
+0.0400 (+2.23%)
since 11/20/24
3-Month
1.2400 +47.58%
on 10/01/24
2.1700 -15.67%
on 12/03/24
+0.4600 (+33.58%)
since 09/20/24
52-Week
0.8000 +128.75%
on 06/26/24
2.4800 -26.21%
on 03/28/24
+0.6300 (+52.50%)
since 12/20/23

Most Recent Stories

More News
New Strong Sell Stocks for December 5th

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Akebia Therapeutics, Inc. AKBA is a biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has...

KOF : 79.63 (+1.25%)
AKBA : 1.8300 (+2.23%)
XRAY : 18.70 (+1.25%)
Akebia Therapeutics: Q3 Earnings Snapshot

Akebia Therapeutics: Q3 Earnings Snapshot

AKBA : 1.8300 (+2.23%)
Talis: Q2 Earnings Snapshot

Talis: Q2 Earnings Snapshot

AKBA : 1.8300 (+2.23%)
Akebia Therapeutics: Q2 Earnings Snapshot

Akebia Therapeutics: Q2 Earnings Snapshot

AKBA : 1.8300 (+2.23%)
Akebia Therapeutics: Q1 Earnings Snapshot

Akebia Therapeutics: Q1 Earnings Snapshot

AKBA : 1.8300 (+2.23%)
Akebia Therapeutics: Q3 Earnings Snapshot

Akebia Therapeutics: Q3 Earnings Snapshot

AKBA : 1.8300 (+2.23%)
Akebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023

/PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.8300 (+2.23%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.8300 (+2.23%)
Akebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat

/PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.8300 (+2.23%)

Business Summary

Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 2.0033
2nd Resistance Point 1.9367
1st Resistance Point 1.8833
Last Price 1.8300
1st Support Level 1.7633
2nd Support Level 1.6967
3rd Support Level 1.6433

See More

52-Week High 2.4800
Fibonacci 61.8% 1.8382
Last Price 1.8300
Fibonacci 50% 1.6400
Fibonacci 38.2% 1.4418
52-Week Low 0.8000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar